Prostate cancer: diagnosis and management

In May 2025 and August 2025, we reviewed this guideline in relation to the section on localised and locally advanced prostate cancer.

Surveillance decision

In May 2025 it was decided that we will update the guideline around docetaxel and abiraterone for high-risk hormone-sensitive non-metastatic prostate cancer. In August 2025 it was decided that we will update the guideline related to the protocol for active surveillance (AS) for localised prostate cancer.